The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema

Expert Review of Respiratory Medicine

Volumn 9, Issue 2, 2015, Pages 143-151

  Franciosi, Alessandro N ^a   McCarthy, Cormac ^a   McElvaney, Noel Gerry ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

a 1 antitrypsin; aerosolized; augmentation; emphysema; inhaled

Indexed keywords

ALPHA 1 ANTITRYPSIN; AEROSOL; SERPINA1 PROTEIN, HUMAN;

AEROSOL; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EMPHYSEMA; HUMAN; IN VITRO STUDY; NONHUMAN; PNEUMONIA; PROTEIN DEGRADATION; TREATMENT OUTCOME; ADVERSE EFFECTS; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMAL; DRUG EFFECTS; ENZYME REPLACEMENT; ENZYMOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG; PATHOPHYSIOLOGY; PULMONARY EMPHYSEMA;

ADMINISTRATION, INHALATION; AEROSOLS; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; ENZYME REPLACEMENT THERAPY; HUMANS; LUNG; PULMONARY EMPHYSEMA; TREATMENT OUTCOME;

EID: 84924991278     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.1002472     Document Type: Article

References (50)

1. Greene CM, McElvaney NG. Proteases and antiproteases in chronic neutrophilic lung disease-relevance to drug discovery. Br J Pharmacol 2009;158(4):1048-58
2. Greene CM, Miller SD, Carroll T, et al. Alpha-1 antitrypsin deficiency: A conformational disease associated with lung and liver manifestations. J Inherit Metab Dis 2008;31(1):21-34
3. Kelly E, Greene CM, Carroll TP, et al. Alpha-1 antitrypsin deficiency. Respir Med 2010;104(6):763-72
4. Petrache I, Fijalkowska I, Medler TR, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 2006;169(4):1155-66
5. Petrache I, Fijalkowska I, Zhen L, et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006;173(11):1222-8
6. Bergin DA, Reeves EP, Meleady P, et al. alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010;120(12):4236-50
7. Bellacen K, Kalay N, Ozeri E, et al. Revascularization of pancreatic islet allografts is enhanced by alpha-1-antitrypsin under anti-inflammatory conditions. Cell Transplant 2012;22(11):2119-33
8. Survival and FEV1 decline in individuals with severe deficiency ofalpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158(1):49-59
9. Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10(10):2260-3
10. Chapman KR, Burdon JG, Piitulainen E, et al. IV Alpha1 Antitrypsin (A1AT) Preserves Lung Density In Homozygous Alpha1 Antitrypsin Deficiency (A1ATD); A Randomized, Placebo-Controlled Trial American journal of respiratory and critical care medicine. C20. Late Breaking Abstracts in Clinical Trials A6069 2013
11. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: A randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009;33(6):1345-53
12. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160(5 Pt 1): 1468-72
13. Mullins CD, Huang X, Merchant S, Stoller JK. The direct medical costs of alpha (1)-antitrypsin deficiency. Chest 2001; 119(3):745-52
14. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009;360(26):2749-57
15. McCarthy C, Dimitrov BD. Augmentation therapy for alpha-1 antitrypsin deficiency-not enough evidence to support its use yet!. Copd 2010;7(3):234-235-6
16. Bergin DA, Reeves EP, Hurley K, et al. The circulating proteinase inhibitor a-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med 2014;6(217):217ra1
17. Sandhaus RA, Turino G. Neutrophil elastase-mediated lung disease. COPD 2013; 10(Suppl 1):60-3
18. Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: molecular pathophysiology. Thorax 2004;59(6):529-35; Review
19. Ogushi F, Fells GA, Hubbard RC, et al. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987;80(5):1366-74
20. Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in a1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014;189(4):419-27
21. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990;85(5):1343-52; Review
22. Hubbard RC, McElvaney NG, Sellers SE, et al. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J Clin Invest 1989;84(4): 1349-54
23. Hubbard RC, Brantly ML, Sellers SE, et al. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med 1989;111(3):206-12
24. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1985; 60(2):532-8
25. Vogelmeier C, Buhl R, Hoyt RF, et al. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol 1990;69(5):1843-8
26. Smith RM, Traber LD, Traber DL, Spragg RG. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep. J Clin Invest 1989;84(4):1145-54
27. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337(8738): 392-4.
28. Griese M, Latzin P, Kappler M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007;29(2):240-50
29. Berger M, Sorensen RU, Tosi MF, et al. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989;84(4):1302-13
30. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007;13(12):1423-30
31. Hill AT, Bayley DL, Campbell EJ, et al. Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000;15(5):886-90
32. Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88(3): 891-7
33. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2002;165(11):1494-8
34. Geraghty P, Rogan MP, Greene CM, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol 2007;178(9):5871-8
35. Taggart CC, Lowe GJ, Greene CM, et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001;276(36):33345-52
36. Rogan MP, Taggart CC, Greene CM, et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 2004;190(7):1245-53
37. Taggart CC, Greene CM, Smith SG, et al. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 2003;171(2):931-7
38. Bergsson G, Reeves EP, McNally P, et al. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 2009;183(1):543-51
39. Geraghty P, Rogan MP, Greene CM, et al. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro. Thorax 2008;63(7):621-6
40. Ma S, Lin YY, He J, et al. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation. COPD 2013;10(4):473-81
41. Brand P, Schulte M, Wencker M, et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009;34(2):354-60
42. Vogelmeier C, Kirlath I, Warrington S, et al. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997;155(2):536-41
43. Kropp J, Wencker M, Hotze A, et al. Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med 2001;42(5):744-51
44. Martin SL, Downey D, Bilton D, et al. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006;41(2):177-83
45. Spencer LT, Humphries JE, Brantly ML; Transgenic Human Alpha 1-Antitrypsin Study Group. Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med 2005; 352(19):2030-1
46. Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990; 168(Suppl):565-78
47. International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema. Available from: https://clinicaltrials.gov/ct2/show/NCT01217671
48. Phase II, Safety and ELF Study of "Kamada-API for Inhalation". Available from: https://clinicaltrials.gov/ct2/show/NCT02001688
49. King MB, Campbell EJ, Gray BH, Hertz MI. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. American journal of respiratory and critical care medicine 1994;149(4 Pt 1):966-71
50. Banga A, Gildea T, Rajeswaran J, et al. The natural history of lung function following lung transplantation for alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2014;190(3):274-81. [Epub ahead of print]